UK pharma major GlaxoSmithKline (LSE: GSK) is hopeful that new data on its systemic lupus erythematosus (SLE) treatment will prompt new approvals in parts of Northeast Asia.
Currently South Korea is the only country in the region where Benlysta (belimumab) has been approved, leaving other parts of Northeast Asia with no approved biologic treatment option for lupus.
GSK believes that this could change based on the new Phase III study findings, which follow three previous positive pivotal trial data sets. The new results have been presented at the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting in Washington DC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze